The GTPase Rab13 regulates the assembly of functional epithelial tight junctions (TJs) through a yet unknown mechanism. Here, we show that expression of the GTP-bound form of Rab13 inhibits PKA-dependent phosphorylation and TJ recruitment of the vasodilator-stimulated phosphoprotein, an actin remodelling protein. We demonstrate that Rab13GTP directly binds to PKA and inhibits its activity. Interestingly, activation of PKA abrogates the inhibitory effect of Rab13 on the recruitment of vasodilator-stimulated phosphoprotein, ZO-1, and claudin1 to cell–cell junctions. Rab13 is, therefore, the first GTPase that controls PKA activity and provides an unexpected link between PKA signaling and the dynamics of TJ assembly.
During epithelial morphogenesis, the development and organization of cell asymmetry require the assembly of functional tight junctions (TJs). TJs serve as a barrier to the paracellular diffusion and prevent the movement of lipids and membrane proteins between apical and basolateral membranes (Tsukita et al., 2001; Matter and Balda, 2003). They form a network of transmembrane, scaffolding, and signaling molecules that control cell–cell adhesion, cell polarity, proliferation, and differentiation (Zahraoui et al., 2000). The TJ transmembrane proteins, claudins, are required for the establishment of TJ gate function (Tsukita and Furuse, 1999). Scaffolding proteins such as ZO-1, a PDZ-containing protein, connect transmembrane proteins to the underlying actin cytoskeleton and recruit cytosolic proteins, such as kinases, GTPases, and transcription factors to TJs (Itoh et al., 1999; Wittchen et al., 1999; Balda and Matter, 2000). The actin cytoskeleton contributes substantially to maintain TJ integrity (Madara et al., 1992). In CaCo-2 cells, disruption of actin filaments with cytochalasin D decreases, and stabilization of F-actin increases barrier function (Madara et al., 1986; Balda et al., 1993). Recently, vasodilator-stimulated phosphoprotein (VASP), a key actin remodelling protein, has been implicated in epithelial TJ biogenesis (Lawrence et al., 2002). VASP was shown to be a substrate for both PKA and PKG (Butt et al., 1994), and phosphorylation of VASP abolishes its interaction with actin and inhibits actin polymerization, assigning VASP a key role in controlling actin dynamics (Harbeck et al., 2000). However, the regulatory pathways that link actin cytoskeleton organization to the assembly of TJ still need to be elucidated. Interestingly, activation of the small GTPases, Rho/Rac, induces the reorganization of the perijunctional actin ring and leads to increased paracellular permeability (Takaishi et al., 1997; Benais-Pont et al., 2003).
Another family of small GTPases, Rab proteins, is also involved in regulating TJ dynamics. Rab GTPases seem to regulate specific membrane transport events including vesicle formation, motility via kinesins or myosins, tethering, and fusion (Pfeffer, 2001; Zerial and McBride, 2001). We have shown previously that Rab13 is recruited from a cytoplasmic pool to cell–cell contacts at an early stage during TJ assembly (Zahraoui et al., 1994; Sheth et al., 2000). Expression of the active (Rab13Q67L), but not the inactive (Rab13T22N) mutant of Rab13 in epithelial MDCK cells delays the recruitment of TJ proteins, claudin1 and ZO-1, and alters TJ integrity. Interestingly, it does not impair the recruitment of E-cadherin to the lateral membrane (Marzesco et al., 2002). Nevertheless, how Rab13 interferes with TJ structure and function is still unclear. In the present work, we show that the active mutant Rab13Q67L inhibits PKA-mediated phosphorylation of VASP and its recruitment to cell–cell junctions. Moreover, Rab13GTP binds to PKA and inhibits its activity. Our data provide new insights into the molecular mechanisms by which Rab13 regulates TJ assembly in epithelial cells.
Results And Discussion
Rab13Q67L prevents the recruitment of VASP to TJs
The effect of GFP-Rab13Q67L on TJ protein recruitment (Marzesco et al., 2002) suggests that Rab13 regulates some aspects of actin cytoskeleton–TJ interactions. Because VASP is involved in the establishment of TJ barrier (Lawrence et al., 2002), we tested whether Rab13 mutants could affect VASP localization during TJ assembly. We used the Ca2+ switch protocol, a model system to study TJ assembly. Cells were plated in medium without Ca2+ for 16 h to dissociate cell–cell junctions, followed by the addition of Ca2+ to trigger synchronous junction assembly. The localization of VASP was analyzed by immunofluorescence at 0, 2, and 4 h after induction of cell–cell contacts. In control cells, as well as in cells expressing GFP-Rab13T22N and Q67L mutants, removal of Ca2+ resulted in the dissociation of cell–cell junctions and redistribution of VASP into the cytoplasm (Fig. 1). Restoration of physiological Ca2+ concentrations induced an increased plasma membrane labeling of VASP at sites of cell–cell contacts in cells expressing GFP or GFP-Rab13T22N. In contrast, in GFP-Rab13Q67L cells, within 4 h after the addition of Ca2+, VASP was not detected at cell–cell contacts and was still cytoplasmic (Fig. 1). This indicated that Rab13Q67L inhibits the recruitment of VASP to sites of cell–cell contacts during junction assembly.
Rab13 controls PKA-dependent phosphorylation of VASP and its subsequent recruitment to cell–cell junctions
Because phosphorylated VASP (P-VASP) accumulates at cell–cell junctions under conditions that enhance barrier recovery, it was proposed that P-VASP is a component of TJs (Lawrence et al., 2002). VASP phosphorylation on residue Ser157 results in a conformational change concomitant with a shift in SDS-PAGE mobility from 46 to 50 kD (Butt et al., 1994). Thus, we tested whether Rab13Q67L could interfere with VASP phosphorylation. Using a monoclonal anti-VASP antibody that recognizes nonphosphorylated as well as P-VASP, we found that in MDCK cells and cells expressing GFP or GFP-Rab13T22N, both forms of VASP were detected. In contrast, in cells expressing GFP-Rab13Q67L, only the 46-kD band corresponding to the nonphosphorylated form of VASP was detected (Fig. 2 A). This indicates that GFP-Rab13Q67L inhibited phosphorylation of VASP at Ser157. To confirm these results, the same cell lysates used in Fig. 2 A were blotted with an anti-VASP antibody that specifically recognizes VASP phosphorylated at Ser157 (P-VASP). This antibody detected the 50-kD band corresponding to P-VASP in cells expressing GFP-Rab13T22N and in control cells, whereas no P-VASP specific band was observed in GFP-Rab13Q67L cell lysate (Fig. 2 B). Thus, the expression of Rab13Q67L specifically inhibits the phosphorylation of VASP at Ser157 in MDCK cells.
VASP phosphorylation at Ser157 was observed upon stimulation of PKA or PKG (Burkhardt et al., 2000). To determine which kinase is responsible for the Rab13-dependent phosphorylation of VASP, we examined the effect of specific kinase inhibitors and activators on VASP phosphorylation. As shown in Fig. 3 A, incubation with both PKG and PKC inhibitors did not significantly reduce the phosphorylation of VASP in control cells or cells expressing GFP-Rab13T22N. In contrast, incubation with the PKA inhibitor H89 decreased the amount of P-VASP in a dose-dependent manner, indicating that the effect on VASP-phosphorylation is specific. Moreover, treatment of cells expressing Rab13Q67L with 8-Br-cGMP, an activator of PKG, did not induce phosphorylation of VASP in those cells. Conversely, activation of PKA by either 8-Br-cAMP or Forskolin restored VASP phosphorylation in GFP-Rab13Q67L cells as monitored by the presence of the 50-kD band of VASP (Fig. 3 B). These data indicate that Rab13-dependent phosphorylation of VASP in MDCK cells is mediated by PKA, but not PKC or PKG.
To investigate whether VASP phosphorylation is required for its recruitment to cell–cell junctions, MDCK cells expressing GFP-Rab13Q67L or GFP-Rab13T22N were incubated with Forskolin and H89, respectively, and P-VASP localization was examined by immunofluorescence using the antibody recognizing P-VASP. In the absence of Forskolin, no P-VASP could be detected at cell–cell junctions in cells expressing GFP-Rab13Q67L (Fig. 3 C). However, activation of PKA by Forskolin restored the recruitment of P-VASP to cell–cell junctions in those cells. In contrast, in cells expressing GFP-Rab13T22N, P-VASP was detected at cell–cell junctions. Treatment of those cells with the specific PKA inhibitor H89 removed P-VASP from cell–cell junctions (Fig. 3 C). Overall, our results demonstrate that activation of Rab13 inhibits PKA-mediated phosphorylation of VASP and prevents its association with intercellular junctions.
Activation of PKA abolishes the inhibitory effect of Rab13Q67L on the recruitment of TJ proteins, ZO-1 and claudin1
To determine whether the effect of Rab13 on claudin1 and ZO-1 recruitment could be mediated by PKA, we examined the consequences of PKA activation on the recruitment of ZO-1 and claudin1 in cells expressing GFP-Rab13Q67L using the Ca2+ switch assay. In control cells as well as in cells expressing GFP-Rab13T22N or GFP-Rab13Q67L, removal of Ca2+ resulted in the dissociation of cell–cell junctions and redistribution of ZO-1 and claudin1 into the cytoplasm (Fig. 4). By 2 h after addition of Ca2+, ZO-1 immunoreactivity was already detected at cell–cell junctions in cells expressing GFP and GFP-Rab13T22N. In contrast, expression of GFP-Rab13Q67L delayed slightly the recruitment of ZO-1; ZO-1 labeling was discontinuous along the lateral membrane. By 4 h after readdition of calcium, ZO-1 staining was detected at the plasma membrane, but some ZO-1 immunoreactivity was still observed in the cytoplasm in cells expressing GFP-Rab13Q67L (Fig. 4 A). Similarly, plasma membrane recruitment of claudin1 was delayed in cells expressing GFP-Rab13Q67L. Within 6–12 h after readdition of calcium, most of the claudin1 staining was still cytoplasmic in GFP-Rab13Q67L cells, whereas claudin1 was detected at the plasma membrane in cells expressing GFP or GFP-Rab13T22N (Fig. 4 B). Significantly, activation of PKA with Forskolin restored the kinetics of both ZO-1 and claudin1 recruitment to the lateral membrane in GFP-Rab13Q67L cells (Fig. 4). This indicates that PKA activation abolished the inhibitory effect of Rab13GTP on the recruitment of TJ proteins, leading to their accumulation at cell–cell junctions. Our data establish that the Rab13–PKA signaling complex plays a key role in TJ biogenesis. They further confirm that PKA-dependent phosphorylation is implicated in the dynamics of epithelial TJ.
Rab13GTP binds to the PKA catalytic subunit and inhibits its activity in vitro
Given that Rab13 interferes with PKA signaling in the regulation of TJ assembly, we wondered whether and how Rab13 interacts with PKA. Thus, we performed a GST pull-down assay from MDCK cell lysates using GST-Rab13 fusion proteins. GST alone or GST-Rab13 were immobilized on glutathione beads, preloaded either with GDP or GTPγS (a poorly hydrolysable GTP analogue), and incubated with MDCK cell lysates. The proteins retained on the beads were separated on SDS-PAGE and blotted with an antibody against the α catalytic subunit of PKA. As shown in Fig. 5 A, the α catalytic subunit of PKA, but not atypical PKCζ (aPKCζ), was preferentially recovered with GST-Rab13 loaded with GTPγS, whereas GST alone did not interact with PKA or aPKCζ. To verify whether the Rab13–PKA interaction is direct, GST-Rab13 loaded with GDP, GTPγS, or GST alone were incubated with a purified preparation of PKA catalytic subunit. Blotting with the anti-PKA antibody revealed that PKA preferentially bound to GST-Rab13-GTPγS, but neither to GST alone, nor to GST-Rab6GTPγS (Fig. 5 B), indicating that Rab13 interacts directly and specifically with the PKA catalytic subunit.
Because the GTP bound form of Rab13 inhibits PKA-dependent VASP phosphorylation in vivo, we next determined whether Rab13GTP interferes with PKA activity in vitro. VASP was immunoprecipitated from cells expressing GFP-Rab13Q67L and used as a physiologically relevant substrate for PKA in a kinase assay. PKI, a potent peptide inhibitor of PKA, was used as a positive control in these experiments. Incubation of VASP with the catalytic subunit of PKA induced VASP phosphorylation in vitro, resulting in a shift in SDS-PAGE mobility from 46 to 50 kD (Fig. 5 C). Similarly to PKI, GST-Rab13-GTPγS caused a strong inhibition of PKA activity, whereas GST alone had no effect. The results in vitro are concordant with those in vivo and demonstrate that Rab13 is able to inhibit PKA activity.
In this paper, we identified PKA as a new effector for the small GTPase Rab13. Our data demonstrate that the GTP bound form of Rab13 directly binds and negatively controls PKA activity both in vitro and in vivo. This is the first demonstration of a biochemical and functional link between a small Rab GTPase and the PKA catalytic subunit.
Protein phosphorylation/dephosphorylation events are required for the regulation of TJ dynamics (Sakakibara et al., 1997; Matter and Balda, 2003). In these processes, VASP may play a key role due to its differential actin binding capacities depending on its state of phosphorylation. Phosphorylation of VASP by PKA reduces VASP–actin interactions and promotes the association of P-VASP with cell–cell junctions. Interestingly, VASP is required for the establishment of cell–cell contacts (Vasioukhin et al., 2000). Although Rab13 does not affect the recruitment of E-cadherin (Marzesco et al., 2002) and β-catenin to cell–cell junctions (Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb.200312118/DC1), we cannot rule out the possibility that Rab13 alters TJ assembly through regulating the recruitment of other adherens junction components. We suggest that Rab13GTP could locally influence actin rearrangement by controlling PKA-dependent VASP phosphorylation and hence inhibit TJ integrity. Our previous data suggested that Rab13, in its GTP-bound form, interacts with an effector that inhibits the recruitment of claudin1 and, to a lesser extent, that of ZO-1 to TJ. Conversely, the inactive form Rab13T22N, unable to bind the effector, favors the establishment of TJ gate and fence functions (Marzesco et al., 2002). The inhibitory effect of the Rab13Q67L mutant on TJ assembly and function could thus be explained by the inhibition of PKA activity. The Rab13–PKA signaling complex may as well regulate vesicle docking near cell–cell junctions. Indeed, PKA activity has been shown to be required for membrane trafficking (Pimplikar and Simons, 1994; Rodionov et al., 2003). Therefore, our observations allow us to postulate the existence of a new signaling cascade at the TJ implicating Rab13–PKA in the dynamics of TJ assembly. They also highlight novel insights into the role of Rab proteins in membrane–cytoskeleton interactions.
Materials And Methods
Anti-VASP mAb was purchased from BD Transduction Laboratories; monoclonal anti-VASP antibody specific for VASP phosphorylated at Ser157 was purchased from NanoTools; polyclonal anti–ZO-1 and anti–claudin-1 antibodies were purchased from Zymed Laboratories; anti-PKA α cat and anti-PKCζ pAbs were purchased from Santa Cruz Biotechnology, Inc. Secondary antibodies coupled to Cy2 or Cy5 were purchased from Jackson ImmunoResearch Laboratories.
MDCK cells (clone II) were cultured in DME supplemented with 10% FCS, 2 mM glutamine, 100 U/ml penicillin, and 10 mg/ml streptomycin. The cells were incubated at 37°C under 10% CO2 atmosphere. MDCK cells stably expressing GFP, GFP-Rab13T22N, or GFP-Rab13Q67L were described previously (Marzesco et al., 2002).
Incubation with kinase inhibitors/activators
500,000 cells were plated onto 3.5-cm diam culture plates overnight and incubated as follows: 1 h at 37°C with 30 μM of PKA inhibitor H-89; 30 min with the PKC and PKG inhibitors Rö-32-0432 (10 μM) or KT5823 (5 μM; Calbiochem); 30 min with 100 μM cAMP or cGMP; or 20 min with 10 μM Forskolin (Sigma-Aldrich). Cells were washed three times in PBS and subjected to either immunofluorescence or immunoblotting procedures. We confirmed that Rö-32-0432 is effective in inhibiting PKC activity under these conditions.
Ca2+ switch experiments
MDCK cells expressing GFP or GFP-Rab13T22N and GFP-Rab13Q67L mutants were plated at a density of 10,000,000 cells/cm2, and incubated for 16 h in S-MEM medium without Ca2+. Cells were rinsed with normal DME, incubated in DME for the indicated time and analyzed by immunofluorescence. When the effect of PKA activation/inhibition was studied, Forskolin and H89 were added to DME after the Ca2+depletion.
Immunofluorescence was performed as described previously (Marzesco et al., 2002). The samples were analyzed with a fluorescence microscope (Carl Zeiss MicroImaging Inc.) and further processed with Adobe Photoshop Software.
Immunoprecipitation and immunoblotting
500,000 MDCK or cells expressing GFP, GFP-Rab13T22N, or GFP-Rab13T22N were grown on 3.5-cm diam culture plates for 16 h, washed three times with ice-cold PBS, and extracted in 0.5% Triton, 10 mM Tris-HCl, pH 7.6, 120 mM NaCl, 25 mM KCl, 1.8 mM CaCl, 1 mM sodium vanadate, 50 mM NaF, and a mixture of protease inhibitors (Sigma-Aldrich) on a rocker platform for 30 min at 4°C. In the GST pull-down experiments, cells were grown on 10-cm diam culture plates for 3 d, washed in PBS, and extracted in the same buffer containing 1% NP-40 instead of Triton X-100. Solubilized material was recovered by pelleting at 18.000 g for 15 min at 4°C. Supernatants were collected and protein concentration determined using the protein assay kit (Bio-Rad Laboratories). For immunoprecipitation, cells expressing GFP-Rab13Q67L were grown for 3 d on 10-cm diam culture plates, washed with PBS, and extracted in IP buffer (50 mM NaCl, 25 mM Tris, pH 8, 1 mM EDTA, 0.25% Triton, 1 mM sodium vanadate, 50 mM NaF, and protease inhibitors). After centrifugation, supernantants were incubated with 5 μg of anti-VASP antibody over night at 4°C. Protein G agarose beads were added for 2 h and the beads washed three times with IP buffer. Equal amount of protein were separated by SDS-PAGE and transferred electrophoretically to nitrocellulose filters. Filters were probed with anti-VASP or anti–P-VASP antibodies before ECL detection according to the manufacturer's protocols (Pierce Chemical Co.).
GST pull-down assay
GST-Rab13 fusion protein was expressed in E. coli and purified according to the manufacturer's protocol (Amersham Biosciences). GST-Rab13 bound to glutathione beads was loaded with 1 mM GDP or GTPγS (a poorly hydrolyzable GTP analogue) for 90 min at RT in incubation buffer (100 mM NaCl, 20 mM Tris, 10 mM EDTA, 5 mM MgCl2, and 1 mM DTT, pH 7.6). After washing, beads were incubated overnight with MDCK cell extracts at 4°C. To prove the direct interaction of Rab13 with PKA, 100 μg of purified PKA catalytic subunit from bovine heart (Sigma-Aldrich) was incubated with a 10-fold molar excess of purified GST, GST-Rab13-GDP, or GST-Rab13-GTPγS proteins in the incubation buffer overnight at 4°C. GST-Rab6 (a gift from B. Goud and S. Monier, UMR144 Institut Curie) was used as negative control. After washing, the extent of PKA binding was determined by SDS-PAGE and Western blotting using polyclonal anti-PKA α cat or anti-PKCζ antibodies.
In vitro kinase assay
10 U of purified PKA catalytic subunit was incubated with VASP immunoprecipitate and either 1 μg of protein kinase inhibitor peptide, PKI (Sigma-Aldrich), and 10 μg of purified GST-Rab13 loaded with GTPγS or GST in kinase buffer (100 mM NaCl, 20 mM Tris, pH 7.5, 10 mM MgCl2, 1 mM DTT, 1 mM ATP) for 30 min at 30°C. The reaction was stopped by adding 3× SDS sample buffer, separated on SDS-PAGE, and VASP phosphorylation determined by Western blot using the anti-VASP antibody.
Online supplemental material
Fig. S1 shows that Rab13 mutants do neither alter the recruitment of adherens junction proteins such as (A) β-catenin or (B) afadin nor (C) cortical actin in a calcium switch experiment. Anti–β-catenin and anti-afadin antibodies were purchased from Sigma-Aldrich and BD Transduction Laboratories, respectively. Phalloidin was purchased from Sigma-Aldrich. Supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.jcb200312118/DC1.
We are grateful to Dr. S. Pfeffer for critical reading of the manuscript, and to Drs. B. Goud and S. Monier for the GST-Rab6 fusion protein.
This work was supported by grants from Centre National de la Recherche Scientifique, Institut Curie, and the Association pour la Recherche sur le Cancer (ARC 3457) to A. Zahraoui. K. Köhler is a recipient of a fellowship from the Swiss National Science Foundation.
The online version of this article contains supplemental material.
Abbreviations used in this paper: aPKCζ, atypical PKCζ; P-VASP, phosphorylated VASP; TJ, tight junction; VASP, vasodilator-stimulated phosphoprotein.